{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:02:26Z","timestamp":1785164546295,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence on the use of glucagon-like peptide-1 (GLP-1) receptor agonists in pediatric obesity remains limited, particularly regarding treatment outcomes, safety, and clinical practice patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate changes in body weight and BMI z-score, assess safety outcomes, and describe treatment patterns among adolescents receiving GLP-1 receptor agonists in routine clinical practice in Saudi Arabia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter retrospective observational study was conducted using medical records of adolescents aged 12\u201318\u202fyears who received GLP-1 receptor agonists between January 2021 and December 2024. Data on demographic and clinical characteristics, treatment patterns, and outcomes were collected. Within-group changes were assessed using the Wilcoxon signed-rank test, and between-group comparisons were performed using the Kruskal\u2013Wallis test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 81 patients were included. GLP-1 therapy was associated with modest reductions in weight and BMI z-score across treatment groups, depending on the GLP-1 receptor agonist used, with no statistically significant differences between groups. Median percentage weight reduction ranged from \u22122 to \u22127%. Adverse events were infrequently documented and, when reported, predominantly gastrointestinal. Endocrinologists issued most prescriptions; the median treatment duration was 4\u202fmonths, dose titration was documented in 37% of patients, and referral for bariatric surgery occurred in 9% of cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In routine clinical practice, GLP-1 receptor agonists were associated with modest weight reduction and were generally well tolerated among adolescents with obesity. Variability in treatment patterns highlights the need for more standardized approaches to optimize the use of GLP-1 therapies in pediatric obesity management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1902763","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:42:45Z","timestamp":1785163365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, safety, and treatment patterns of GLP-1 receptor agonists in adolescents with obesity: a multicenter retrospective study from Saudi Arabia"],"prefix":"10.3389","volume":"13","author":[{"given":"Farah","family":"Kalagi","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Public Health, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Hamed","sequence":"additional","affiliation":[{"name":"Institutional Review Board (IRB), SMC Healthcare","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadeem","family":"Alrubaian","sequence":"additional","affiliation":[{"name":"Clinical Nutrition Department, Dr. Sulaiman Al Habib Hospital","place":["Al-Khobar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimah","family":"Almuzain","sequence":"additional","affiliation":[{"name":"Medical Allied Services Department, Imam Abdulrahman Bin Faisal University \u2013 King Fahd Hospital of the University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisreen","family":"Alturkestany","sequence":"additional","affiliation":[{"name":"Clinical Nutrition Department, Dr. Sulaiman Al Habib Hospital","place":["Al-Khobar, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulaiman","family":"Bah","sequence":"additional","affiliation":[{"name":"Department of Public Health, College of Public Health, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Algindan","sequence":"additional","affiliation":[{"name":"Department of Clinical Nutrition, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University","place":["Dammam, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref1","year":"2025"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","author":"Kerr","year":"2025","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e13817","DOI":"10.1111\/obr.13817","article-title":"Efficacy of lifestyle interventions to treat pediatric obesity: a systematic review and multivariate meta-analysis of randomized controlled trials","volume":"25","author":"Deng","year":"2024","journal-title":"Obes Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","article-title":"Pediatric obesity\u2014assessment, treatment, and Prevention: an Endocrine Society clinical practice Guideline","volume":"102","author":"Styne","year":"2017","journal-title":"J Clin Endocrinol Metabol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/s41366-018-0230-y","article-title":"Interventions for treating children and adolescents with overweight and obesity: an overview of Cochrane reviews","volume":"42","author":"Ells","year":"2018","journal-title":"Int J Obes"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","article-title":"Clinical practice Guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly Semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jamapediatrics.2025.3243","article-title":"Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type 2 diabetes: a systematic review and Meta-analysis","volume":"179","author":"Kotecha","year":"2025","journal-title":"JAMA Pediatr"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2024068119","DOI":"10.1542\/peds.2024-068119","article-title":"GLP-1 receptor agonists in pediatric and adolescent obesity","volume":"155","author":"Stefater-Richards","year":"2025","journal-title":"Pediatrics"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.4103\/sjg.sjg_455_25","article-title":"Efficacy and safety of glucagon-like peptide-1 (GLP-1) agonists in pediatric obesity: a systematic review and meta-analysis","volume":"32","author":"Sukkar","year":"2026","journal-title":"Saudi J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3390\/ph17070828","article-title":"Comparative efficacy and safety of glucagon-like Peptide-1 receptor agonists in children and adolescents with obesity or overweight: a systematic review and network Meta-analysis","volume":"17","author":"Liu","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.15585\/mmwr.mm7420a1","article-title":"Prescriptions for obesity medications among adolescents aged 12\u201317 years with obesity \u2014 United States, 2018\u20132023","volume":"74","author":"Kompaniyets","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/ijpo.13146","article-title":"Primary care perspectives on prescribing anti-obesity medication for adolescents","volume":"19","author":"Chivate","year":"2024","journal-title":"Pediatr Obes"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1663499","DOI":"10.3389\/fendo.2025.1663499","article-title":"12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data","volume":"16","author":"Cominato","year":"2025","journal-title":"Front Endocrinol"},{"key":"ref16","year":"2022"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3390\/children12121716","article-title":"Real-world use of GLP-1 receptor agonist Liraglutide in adolescents with obesity: a first longitudinal single-center analysis from Switzerland","volume":"12","author":"Noordam","year":"2025","journal-title":"Children"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/21532176251385715","article-title":"Adherence and effectiveness of Liraglutide in adolescents with obesity","volume":"22","author":"Yaron","year":"2025","journal-title":"Child Obes"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e47994","DOI":"10.1097\/MD.0000000000047994","article-title":"GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Ahmad","year":"2026","journal-title":"Medicine"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12902-026-02273-3","article-title":"Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1\u2013based therapies: a retrospective observational study in the United Arab Emirates","volume":"26","author":"Almemari","year":"2026","journal-title":"BMC Endocr Disord"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5144\/0256-4947.2025.129","article-title":"Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta-analysis","volume":"45","author":"Safwan","year":"2025","journal-title":"Ann Saudi Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s43440-024-00629-x","article-title":"A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment","volume":"76","author":"Tobaiqy","year":"2024","journal-title":"Pharmacol Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.2147\/DMSO.S552287","article-title":"Knowledge, counseling practice, perceived barriers, and clinical decision-making of community pharmacists in Saudi Arabia regarding glucagon-like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors","volume":"18","author":"Alhomoud","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref25","year":"2023"},{"key":"ref26","year":"2025"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1902763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:42:46Z","timestamp":1785163366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1902763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":26,"alternative-id":["10.3389\/fnut.2026.1902763"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1902763","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1902763"}}